TORRENT PHARMACEUTICALS LTD. - 500420 - Business Responsibility and Sustainability Reporting (BRSR)
Pursuant to Regulation 34(2)(f) of SEBI Listing Regulations, please find enclosed herewith Business Responsibility and Sustainability Report (BRSR) for the FY 2022-23 TORRENT PHARMACEUTICALS LTD. - 500420 - Reg. 34 (1) Annual Report.
Please find attached herewith soft copy of the Integrated Annual Report 2022-23 (comprising of Notice calling 50th Annual General Meeting (AGM) along with Audited Financial Statements, Directors'' Report, Auditors' Report, etc.) of Torrent Pharmaceuticals Limited ("the Company") in compliance with Regulation 34(1)(a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('the Listing Regulations'). The above is for your information and record.
Torrent Pharma Q1 PAT may dip 9.7% YoY to Rs 319.7 cr: Nirmal Bang
Net Sales are expected to increase by 11 percent Y-o-Y (up 4.6 percent Q-o-Q) to Rs 2,604.6 crore, according to Nirmal Bang. TORRENT PHARMACEUTICALS LTD. - 500420 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of issue of Duplicate Share Certificates TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper advertisement - Intimation of the 50th Annual General Meeting of the Company through Video-Conferencing / Other Audio Visual Means ("VC / OAVM") facility. TORRENT PHARMACEUTICALS LTD. - 500420 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of Loss of Share Certificates TORRENT PHARMACEUTICALS LTD. - 500420 - Closure of Trading Window
Intimation of Closure of Trading Window as per Company''s Code of Conduct to Regulate, Monitor and Report Trading by Designated Persons TORRENT PHARMACEUTICALS LTD. - 500420 - USFDA Pre-Approval Inspection Of Oral Oncology Manufacturing Facility, Gujarat
We refer to our earlier letter dated 17-Mar-23 regarding USFDA Pre- Approval Inspection [PAI] of our Oral- Oncology manufacturing facility at Bileshwarpura, Gujarat. In furtherance to the aforementioned intimation, this is to inform you that USFDA has issued an Establishment Inspection Report (EIR) for the said manufacturing facility and the inspection has now been successfully closed by the USFDA. Please take the information on record. TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
In continuation of our letter dated 16-May-23 and pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Transcript of Conference call with Analysts / Investors on Audited Financial Results of the Company for the quarter and year ended 31st March, 2023, has been placed on the Company's website at https://www.torrentpharma.com/pdf/investors/Earnings_Call_Transcript_May_30_2023.pdf
Hold Torrent Pharmaceuticals; target of Rs 1910: Sharekhan
Sharekhan recommended Hold rating on Torrent Pharmaceuticals with a target price of Rs 1910 in its research report dated May 31, 2023.